No Data
No Data
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders would be excited to see that the share price has had a great month, posting a 33% gain and recovering from prior weakness. Looking further back,
BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $5
BTIG analyst Julian Harrison maintains $Akebia Therapeutics(AKBA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 48.2% and
Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) marginally higher and the iShares Biotechnology ETF (IBB) up 1.1% recently.Pfizer (PFE) rose
Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit
No Data
DamYankee : did not see that coming. You think it will drop back down to a dollar flat?
TrytosaveabitOP DamYankee: I mean anything is possible? But me personally im not looking for it unless shorts come at it hard this week
TrytosaveabitOP DamYankee: It was pretty good PR
DamYankee TrytosaveabitOP: I jumped into IVP instead. Got in at 5 dollars and some change. literally doubled right after the order got filled. lady luck was on my side lol. I'm hoping it still has potential to hit 14.75 again. Also started CDT today at .253
TrytosaveabitOP DamYankee: Congrats on a killer trade!
View more comments...